Intracranial administration of anti-PD-1 and anti-CTLA-4 immune checkpoint-blocking monoclonal antibodies in patients with recurrent high-grade glioma
Intraoperative iCer IPI + NIVO with postoperative iCav NIVO ± IPI up to biweekly doses of 1 mg IPI + 10 mg NIVO is feasible and safe, showing encouraging OS in rHGG patients. ClinicalTrials.gov registration: NCT03233152.
Authors
- Michaël Bruneau (ORCID: https://orcid.org/0000-0002-3612-6647)
- Hendrik Everaert (ORCID: https://orcid.org/0000-0003-0756-0089)
- Louise Lescrauwaet
- Johnny Duerinck (ORCID: https://orcid.org/0000-0001-9869-9806)
- Jacomi Del’haye
- Freya Vaeyens (ORCID: https://orcid.org/0000-0002-6270-6653)
- Xenia Geeraerts (ORCID: https://orcid.org/0000-0003-0163-9482)
- Mark Kockx (ORCID: https://orcid.org/0000-0001-9147-2975)
- Anne‐Marie Vanbinst (ORCID: https://orcid.org/0000-0003-4867-6133)
- Isabelle Salmon (ORCID: https://orcid.org/0000-0002-7732-2863)
- Ben Caljon
- Wietse Geens (ORCID: https://orcid.org/0000-0002-2496-9209)
- Laetitia Lebrun (ORCID: https://orcid.org/0000-0002-5663-8180)
- Sandra Tuyaerts (ORCID: https://orcid.org/0000-0003-1255-8071)
- Stefanie Brock (ORCID: https://orcid.org/0000-0002-4137-512X)
- Iris Dirven (ORCID: https://orcid.org/0000-0003-2168-0781)
- Bart Neyns (ORCID: https://orcid.org/0000-0003-0658-5903)
- Latoya Stevens (ORCID: https://orcid.org/0000-0003-4668-9854)
Institutions
- Université Libre de Bruxelles (BE)
- Vrije Universiteit Brussel (BE)
- Erasmus Hospital (BE)
- Universitair Ziekenhuis Brussel (BE)
- Molecular Oncology (United States) (US)
- Cell Medica (Switzerland) (CH)
Publication Details
- Journal
- Neuro-Oncology
- Published
- 2024-10-16
- DOI
- https://doi.org/10.1093/neuonc/noae177
- Citations
- 24
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 10.51
Funders
- Vrije Universiteit Brussel